logo

For the Inventor, By the Inventor

Braine le Chateau, Belgium

David Communi

USPTO Granted Patents = 12 



Average Co-Inventor Count = 8.6

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Braine-le-Chateau, BE (2008 - 2011)
  • Braine Le Chateua, BE (2010 - 2011)

Company Filing History:

goldMedal10 out of 33 
 
Euroscreen S.a.
 patents
silverMedal2 out of 832,843 
Other
 patents

Years Active: 2008-2011

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 8030453 - Methods of making an antibody that binds a chemerin polypeptide (2011-10-04),
2. 8003347 - Nucleic acids encoding ChemerinR ligands (2011-08-23),
3. 7858755 - Monoclonal antibodies that bind Chemerin polypeptide (2010-12-28),
4. 7842795 - Nucleic acids encoding a heme binding protein polypeptide (2010-11-30),
5. 7842453 - Methods of identifying modulators of ChemerinR polypeptides (2010-11-30),
6. 7666401 - Compositions comprising a ligand of Chemerin R (2010-02-23),
7. 7659251 - Ligand for G-protein coupled receptor FPRL2 (2010-02-09),
8. 7582734 - Functional antibodies that specifically bind to the Chemerin receptor (2009-09-01),
9. 7582416 - Ligand for G-protein coupled receptor FPRL2 and uses thereof (2009-09-01),
10. 7470772 - Antibody that specifically binds to Chemerin receptor ligand precursor (2008-12-30),
11. 7419658 - Isolated ligand of ChemerinR (2008-09-02),
12. 7332291 - Methods of identifying modulators of ligand binding to ChemerinR polypeptides (2008-02-19),

Title: The Innovative Mind of David Communi

Introduction

David Communi is a prominent inventor based in Braine le Chateau, Belgium. He has made significant contributions to the field of biotechnology, holding a notable portfolio of 12 patents. His work primarily focuses on the development of methods and compounds integral to medical science, particularly involving G-protein coupled receptors.

Latest Patents

Among David's latest innovations are groundbreaking patents related to antibodies that bind to chemerin polypeptides. His inventions delve into creating screening assays that identify candidate compounds to modulate the activity of G-protein coupled receptors. Furthermore, these patents are critical for diagnosing and treating diseases connected to the dysregulation of G-protein coupled receptor signaling. This innovative approach not only showcases his expertise but also his commitment to advancing medical research and therapeutic options.

Career Highlights

David has built a distinguished career, working with reputable companies, including Euroscreen S.A. His contributions at Euroscreen have significantly influenced the company's direction and innovations within the biopharmaceutical sector. David's patents reflect a deep understanding of molecular biology and an ability to translate complex concepts into practical applications, fostering advancements in therapeutic treatments.

Collaborations

Throughout his career, David has collaborated with esteemed professionals such as Isabelle Migeotte and Marc Parmentier. These collaborations have enriched his research and have allowed for a multidisciplinary approach, combining different areas of expertise to enhance the quality and efficacy of his inventions.

Conclusion

David Communi continues to be a key figure in the realm of biotechnological innovations. His work not only exemplifies the spirit of invention but also opens avenues for future research and development in medicine. As David progresses in his career, the impact of his patents is likely to resonate throughout the scientific community and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…